XETRA - Delayed Quote ? EUR Vertex Pharmaceuticals Incorporated (VX1.DE) Follow Compare 447.30 -1.70 (-0.38%) At close: October 18 at 5:35 PM GMT+2 All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Prediction: These 2 Stocks Will Beat the S&P 500 Through 2030 There's no need to change a winning formula. Motley Fool ? yesterday VRTX HCA ^GSPC Vertex to Present Phase 3 Data Highlighting Suzetrigine’s Potential as a First-in-Class, Highly Selective Pain Signal Inhibitor at the American Society of Anesthesiologists Annual Meeting BOSTON, October 18, 2024--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the company will present its pivotal Phase 3 data on suzetrigine, an investigational, oral, highly selective NaV1.8 pain signal inhibitor for the treatment of moderate-to-severe acute pain, at the annual meeting of the American Society of Anesthesiologists (ASA), taking place from October 18-22, 2024 in Philadelphia, Pennsylvania. Business Wire ? 2 days ago VRTX Exploring 3 High Growth Tech Stocks in the United States Over the last 7 days, the United States market has risen by 1.2%, contributing to a substantial increase of 35% over the past year, with earnings expected to grow by 15% per annum in the coming years. In this favorable market environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability to capitalize on these positive trends. Simply Wall St. ? 3 days ago VRTX ADSK TTD Vertex Pharmaceuticals (VRTX) Ascends But Remains Behind Market: Some Facts to Note Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $484.94, moving +0.67% from the previous trading session. Zacks ? 6 days ago VRTX Got $1,000? 2 Magnificent Growth Stocks to Buy and Hold Forever These profitable companies are facing long-term growth runways. Motley Fool ? 7 days ago VRTX PLTR 3 No-Brainer Growth Stocks to Buy in October These stocks look like slam-dunk picks for growth investors. Motley Fool ? 7 days ago VRTX LLY NVO Vertex to Announce Third Quarter 2024 Financial Results on November 4th BOSTON, October 10, 2024--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2024 financial results on Monday, November 4, 2024 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the "Vertex Pharmaceuticals Third Quarter 2024 Earnings Call." Business Wire ? 10 days ago VRTX October 2024's US Stocks That May Be Trading Below Estimated Fair Value As the U.S. stock market continues its impressive rally, with the S&P 500 and Dow Jones Industrial Average reaching record highs, investors are increasingly focused on identifying opportunities that may be trading below their estimated fair value. In this buoyant market environment, a good stock is often characterized by strong fundamentals and potential for growth that hasn't yet been fully recognized by the broader market. Simply Wall St. ? 10 days ago VRTX PLTR AMD Vertex Pharmaceuticals Inc (VRTX) Q2 2024 Earnings Call Highlights: Navigating Growth Amidst ... Vertex Pharmaceuticals Inc (VRTX) reports robust revenue growth and raises guidance, while addressing acquisition-related losses and strategic hurdles. GuruFocus.com ? 11 days ago VRTX 2 Biotech Stocks to Buy Hand Over Fist in October These longtime leading biotech stocks still have plenty of upside ahead. Motley Fool ? 11 days ago VRTX AMGN Here is What to Know Beyond Why Vertex Pharmaceuticals Incorporated (VRTX) is a Trending Stock Recently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store. Zacks ? 11 days ago VRTX Is Vertex Pharmaceuticals Incorporated (VRTX) Positioned for Continued Success in Cystic Fibrosis and Beyond? We recently published a list of Renaissance Technologies Portfolio: 10 Best Stocks To Buy. In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against the other best stocks to buy which are part of the Renaissance Technologies portfolio. Renaissance Technologies is an American hedge fund that specializes […] Insider Monkey ? 11 days ago VRTX Vertex Pharmaceuticals (VRTX) Registers a Bigger Fall Than the Market: Important Facts to Note Vertex Pharmaceuticals (VRTX) concluded the recent trading session at $448.16, signifying a -1.57% move from its prior day's close. Zacks ? 13 days ago VRTX ^GSPC Zacks Market Edge Highlights: Vertex, Zillow RH, Super Micro Computer, Yum China Vertex, Zillow RH, Super Micro Computer, Yum China have been highlighted in this Market Edge article. Zacks ? 13 days ago YUMC VRTX ZG Insider Trades: How to Find the Top Stocks Tracey is joined by Asif Suria, author of The Event-Driven Edge in Investing, to talk about how to get an edge from insider trading. Zacks ? 16 days ago VRTX YUMC ZG DRI Healthcare Trust Buying Payment Streams Based On Gene-Editing Technology For US$57 Million DRI Healthcare Trust Buying Payment Streams Based On Gene-Editing Technology For US$57 Million PREMIUM MT Newswires ? 16 days ago VRTX HR EDIT 3 Top Stocks That Could Still Rocket Higher in 2024 Upcoming Food and Drug Administration decisions could push these stocks through the roof. Motley Fool ? 16 days ago BBIO VRTX PTCT 2 Superior Growth Stocks That Are Screaming Buys Right Now These companies have plenty of growth runway left. Motley Fool ? 16 days ago VRTX NFLX Reasons that Lifted Vertex Pharmaceuticals Incorporated (VRTX) in Q2 PGIM Jennison Health Sciences Fund released its second quarter 2024 investor letter. A copy of the letter can be downloaded here. The fund modestly underperformed the S&P 1500 Health Care Index in the quarter which declined 1.1%. Security selection within pharmaceuticals, MedTech, and health care provides & services contributed the most value during the quarter, […] Insider Monkey ? 17 days ago VRTX 5 FDA decisions to watch in the fourth quarter Over the next three months, the agency could approve a rival to a fast-selling Pfizer heart drug, a much-debated lung cancer medicine and an addition to Vertex's dominant cystic fibrosis business. BioPharma Dive ? 19 days ago BBIO VRTX CELG-RT Performance Overview Trailing total returns as of 10/18/2024, which may include dividends or other distributions. Benchmark is S&P 500 Return VX1.DE S&P 500 YTD +20.50% +22.95% 1-Year +26.73% +34.10% 3-Year +184.54% +31.16%
